Hematologic Oncology

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

A recent study, published in Blood Advances, has identified that pre-HSCT conditioning induces the extracellular release of damaged mitochondria, exacerbating GVHD.

A recent study, published in Cell, has identified the circadian rhythm of TILs as a key determinant in the efficacy of immunotherapy treatments such as CAR T-cell therapy and immune checkpoint blockade.

Cyclophosphamide-based prophylaxis for GVHD showed similar outcomes across racial subgroups regardless of matched or mismatched unrelated donors.

Mismatched unrelated donor consideration may expand donor numbers, especially for those with minority ancestry seeking hematopoietic cell transplantation.

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

After allogeneic hematopoietic cell transplantation, pregnancies could be carried out and were successful.

Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.

In a collaborative effort between 18 centers, researchers have developed a system that effectively stratifies children at the onset of acute graft versus host disease for risk of non-relapse mortality over 6 months.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.

Phase 1 data show no dose-limiting toxicities with sonrotoclax plus zanubrutinib for patients with relapsed/refractory CLL or SLL.

Data from the phase 3b JUMP trial support the use of ruxolitinib in myelofibrosis regardless of baseline or treatment-related anemia.

Progression-free survival and overall survival appear to be shorter in patients with TP53-mutant CLL vs those with TP53 wild-type disease.

The novel antibiotic lock solution Mino-Lok could help treat catheter-related infections that patients with cancer may experience.

Phase 1/2 data highlight the benefit of linvoseltamab even among prespecified high-risk patient subgroups with relapsed/refractory multiple myeloma.

Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.

A cohort study of the KarMMa-2 trial found durable responses in patients with high-risk multiple myeloma treated with ide-cel.

The likelihood of response was also higher in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.

Data from STARGLO showed that fixed-duration glofitamab-gxbm (Columvi) plus gemcitabine/oxaliplatin significantly improved survival compared with rituximab (Rituxan) plus gemcitabine/oxaliplatin in select patients with relapsed/refractory diffuse large B-cell lymphoma.

Blinatumomab demonstrated “impressive activity” in the ALLTogether1 DS study, according to Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD.

Data from the REVEAL trial support identifying history of thromboembolic events as a potential novel risk factor in those with polycythemia vera.

Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.

More than half of the patients included in the phase 1b BP41072 study achieved a complete response to englumafusp alfa plus glofitamab.

High-grade cytokine release syndrome in the WU-CART-007 1001 trial was manageable with supportive care.

The rate of disease progression among patients with low- or intermediate-risk myelofibrosis appeared to increase over time in the MOST study.

Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.

Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.

Those with relapsed/refractory multiple myeloma and lower tumor burden are also more likely to have deeper responses to idecabtagene vicleucel.